Houston pharmacy recalls glutathione IV vials as multistate contamination probe widens

A Houston compounding pharmacy has become the third such firm in six weeks to pull injectable glutathione products from the market after finding elevated levels of bacterial toxins in the raw ingredient, deepening a multistate health investigation into a wellness treatment marketed at medical spas and IV therapy clinics across the country.

Centric Compounding LLC recalled six lots of Glutathione 200 mg/mL, Myer's Cocktail and Tri-Immune Boost injectable vials on September 9, saying pharmacy testing had found elevated endotoxin levels in the glutathione active ingredient used to make them. The company, which distributed the 30-milliliter multidose vials nationwide through home delivery and to prescribing clinicians, said it had received nine reports of adverse reactions, including fever, chills, chest pain, nausea, vomiting, headache and malaise.

A pattern emerges

The Centric recall follows an Austin pharmacy's recall of three glutathione lots in early August and a Houston competitor's recall of a single lot two weeks later, both tied to the same category of contamination. Victory Medical Center Pharmacy's recalled vials, sent to patients in Texas, Florida and New York, were linked to reports of fever, chills, severe headache, nausea, vomiting, rapid heartbeat, blood-pressure swings, body aches and injection-site reactions. Optimal Balance Pharmacy's single recalled lot had reached patients in fourteen states, from Washington and Nevada to Vermont and Pennsylvania, before it was pulled.

The Centers for Disease Control and Prevention says the underlying investigation, which began after Texas health officials flagged sickened patients in July, has now documented more than 25 illnesses across at least four states: Texas, Washington, Florida and New York. At least three patients have been hospitalized, and one became critically ill and required intensive care, the agency said in an update this week. It cautioned that the count of patients and states could rise as the inquiry continues.

Why a supplement-grade ingredient ended up in a syringe

Glutathione is a naturally occurring antioxidant that the body produces on its own. Sold over the counter as an oral supplement, it has also become a fixture of the IV-wellness industry, marketed by medical spas and infusion clinics as a treatment for fatigue, skin brightening and general detoxification, despite thin clinical evidence for those claims when delivered intravenously. Because those injectable formulations are custom-mixed by compounding pharmacies rather than manufactured and tested the way FDA-approved drugs are, they fall under a lighter regulatory framework that relies heavily on the ingredients pharmacies choose to buy and the quality control they apply themselves.

In the cases under investigation, regulators say pharmacies obtained glutathione that was manufactured and labeled for use in dietary supplements, not for sterile injection, and used it to compound the IV products anyway. On August 27, the FDA formally reminded compounders that dietary-supplement-grade glutathione is unsuitable for sterile injectable production, warning that such material can carry endotoxins and other impurities that manufacturing standards for injectable drugs are specifically designed to exclude. The agency traced the problematic material, at least in part, to a lot distributed by the ingredient supplier Medisca Inc., based in Plattsburgh, New York, which it said had been labeled for dietary-supplement use rather than for compounding sterile drugs.

Endotoxins are components of the outer membrane of certain bacteria that can trigger a severe inflammatory response when they enter the bloodstream directly, bypassing the body's usual defenses against bacteria ingested by mouth. The FDA has said injectable products contaminated with elevated endotoxin levels carry a reasonable probability of causing fever, dangerously low blood pressure, inflammatory reactions, anaphylactic shock and death.

Who has been affected

The recalled vials were sold to wellness clinics, medical spas and prescribing physicians who then administered them to patients seeking routine infusions, not to consumers buying the products directly off a shelf. That has complicated the response: many patients who received an affected dose may not know which lot number was used or that a recall has since been issued. Some patients seeking these treatments include firefighters and emergency responders, whose union, the International Association of Fire Fighters, circulated a safety advisory to its locals in August flagging the recalls and the FDA's concerns about supplement-grade glutathione in injectable products.

Litigation has already followed. A Texas woman filed suit in Travis County against Victory Medical Center Pharmacy last month after she received an infusion from one of the recalled lots at a wellness clinic in June and was taken by ambulance to a hospital within minutes of the treatment, according to a statement from her attorneys announcing the lawsuit. The suit alleges negligence, products liability and gross negligence, and her lawyers say they are now reviewing potential claims from patients of all three pharmacies involved in the recalls.

"Our client sought a routine wellness infusion and, within minutes, suffered symptoms that led to ambulance transport and hospitalization," attorney John David Hart said in the statement announcing the suit.

Reaction and the response so far

All three pharmacies have described their recalls as voluntary and say they are cooperating with regulators. Centric Compounding is directing questions from patients and prescribers to a dedicated phone line, and Optimal Balance Pharmacy and Victory Medical Center Pharmacy have set up similar contact points listed in their FDA recall notices. None of the three companies has disclosed the results of any internal review of how the contaminated ingredient entered their supply chains beyond attributing it to the glutathione raw material itself.

Coverage of the Centric recall spread quickly through Texas outlets this week, with local reporting describing it as the third such endotoxin scare tied to Texas compounders in a matter of weeks, underscoring how concentrated the cluster of recalls has been in a single state's compounding industry even as the FDA's warning and the CDC's case count point to effects felt well beyond it.

What happens next

The FDA has asked prescribers and patients to check whether any glutathione, Myer's Cocktail or Tri-Immune Boost product they have received or dispensed matches one of the recalled lot numbers, and to report any adverse reactions through the agency's MedWatch program. The CDC's investigation remains open, and the agency has said the number of confirmed illnesses and affected states is likely to change as additional cases are identified and reported by state health departments. Regulators have not said whether they intend to pursue action against Medisca Inc., the supplier whose dietary-supplement-labeled glutathione the FDA has linked to the recalls, and the company had not issued its own public recall notice as of this week.

For now, the episode has put a spotlight on a corner of the wellness industry that has grown largely outside the scrutiny applied to conventional pharmaceuticals: intravenous infusions sold at spas and boutique clinics as quick fixes for fatigue and appearance, compounded from ingredients whose suitability for injection is not always independently verified before a needle goes into a patient's arm.